EMAIL THIS PAGE TO A FRIEND

Molecular cancer therapeutics

The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis.


PMID 25673819

Abstract

The IGFI receptor promotes malignant progression and has been recognized as a target for cancer therapy. Clinical trials with anti-IGFIR antibodies provided evidence of therapeutic efficacy but exposed limitations due in part to effects on, and the compensatory function of, the insulin receptor system. Here, we report on the production, characterization, and biologic activity of a novel, IGF-targeting protein (the IGF-Trap) comprising a soluble form of hIGFIR and the Fc portion of hIgG1. The IGF-Trap has a high affinity for hIGFI and hIGFII but low affinity for insulin, as revealed by surface plasmon resonance. It efficiently blocked IGFIR signaling in several carcinoma cell types and inhibited tumor cell proliferation, migration, and invasion in vitro. In vivo, the IGF-Trap showed favorable pharmacokinetic properties and could suppress the growth of established breast carcinoma tumors when administered therapeutically into tumor-bearing mice, improving disease-free survival. Moreover, IGF-Trap treatment markedly reduced experimental liver metastasis of colon and lung carcinoma cells, increasing tumor cell apoptosis and reducing angiogenesis. Finally, when compared with an anti-IGFIR antibody or IGF-binding protein-1 that were used at similar or higher concentrations, the IGF-Trap showed superior therapeutic efficacy to both inhibitors. Taken together, we have developed a targeted therapeutic molecule with highly potent anticancer effects that could address limitations of current IGFIR-targeting agents.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

C3161
Calcium phosphate tribasic, BioReagent, plant cell culture tested, powder
HCa5O13P3
C5267
Calcium phosphate tribasic, 34.0-40.0% Ca basis
HCa5O13P3
RAB0228
Human IGF-I ELISA Kit, for serum, plasma, cell culture supernatant and urine
RAB0230
Human IGF-I R ELISA Kit, for serum, plasma, cell culture supernatant and urine
702153
Hydroxyapatite, nanoparticles, dispersion, 10 wt. % in H2O, <200 nm particle size (BET)
Ca5HO13P3
H0252
Hydroxyapatite, Type I, buffered aqueous suspension
HCa5O13P3
55497
Hydroxyapatite, ′fast flow′
HCa5O13P3
04238
Hydroxyapatite, puriss., meets analytical specification of Ph. Eur., BP, FCC, E341, ≥90% (calculated on glowed substance)
HCa5O13P3
574791
Hydroxyapatite, synthetic, 99.8% trace metals basis (excludes Mg)
HCa5O13P3
21223
Hydroxyapatite, purum p.a., ≥90% (as Ca3(PO4)2, KT)
HCa5O13P3
289396
Hydroxyapatite, reagent grade, powder, synthetic
HCa5O13P3
677418
Hydroxyapatite, nanopowder, <200 nm particle size (BET), ≥97%, synthetic
HCa5O13P3
693863
Hydroxyapatite, nanopowder, <200 nm particle size (BET), contains 5 wt. % silica as dopant, synthetic
HCa5O13P3
RAB0229
Mouse IGF-I ELISA Kit, for serum, plasma and cell culture supernatant
RAB0800 Mouse Igf1r / Insulin-like Growth Factor 1 Receptor ELISA Kit
RAB0012 Phospho-Akt (pSer473) / pan-Akt ELISA Kit, for detection of human, mouse or rat phospho-akt (pSer473) and pan-akt in cell and tissue lysates
RAB0011 Phospho-Akt (pSer473) ELISA Kit, for detection of human, mouse or rat phospho-akt (pSer473) in cell and tissue lysates